Zobrazeno 1 - 10
of 140
pro vyhledávání: '"Esther H Lips"'
Autor:
Maartje vanSeijen, Katarzyna Jóźwiak, Sarah E Pinder, Allison Hall, Savitri Krishnamurthy, Jeremy SJ Thomas, Laura C Collins, Jonathan Bijron, Joost Bart, Danielle Cohen, Wen Ng, Ihssane Bouybayoune, Hilary Stobart, Jan Hudecek, Michael Schaapveld, Alastair Thompson, Esther H Lips, Jelle Wesseling, The Grand Challenge PRECISION consortium.
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 7, Iss 3, Pp 233-242 (2021)
Abstract The prognostic value of cytonuclear grade in ductal carcinoma in situ (DCIS) is debated, partly due to high interobserver variability and the use of multiple guidelines. The aim of this study was to evaluate interobserver agreement in gradin
Externí odkaz:
https://doaj.org/article/018d235b3e01461b8b9e9bd581a263c5
Autor:
Marcelo Sobral-Leite, Esther H Lips, Hayra de Andrade Vieira-Monteiro, Letícia Carlos Giacomin, Daniely Regina Freitas-Alves, Sten Cornelissen, Lennart Mulder, Jelle Wesseling, Marjanka K Schmidt, Rosane Vianna-Jorge
Publikováno v:
PLoS ONE, Vol 12, Iss 12, p e0189750 (2017)
Pathological response of breast cancer to neoadjuvant chemotherapy (NAC) presents great variability, and new prognostic biomarkers are needed. Our aim was to evaluate the association of the epidermal growth factor receptor gene (EGFR) polymorphism R4
Externí odkaz:
https://doaj.org/article/921831b4e3b344b0bb026f69b6eaf0f3
Autor:
E.G. Engelhardt, R.S.J.M. Schmitz, M.A. Gerritsma, C.M.T. Sondermeijer, E. Verschuur, J.H.E. Houtzager, R. Griffioen, N. Bijker, R.M. Mann, V. Retèl, F.H. van Duijnhoven, J. Wesseling, E.M.A. Bleiker, Alastair Thompson, Serena Nik-Zainal, Elinor J. Sawyer, Helen Davies, Andrew Futreal, Nicholas Navin, E. Shelley Hwang, Jos Jonkers, Jacco van Rheenen, Fariba Behbod, Esther H. Lips, Marjanka Schmidt, Lodewyk F.A. Wessels, Daniel Rea, Proteeti Bhattacharjee, Hilary Stobart, Deborah Collyar, Donna Pinto, Marja van Oirsouw, S. Alaeikhanehshir, L. Elshof
Publikováno v:
Breast, Vol 77, Iss , Pp 103764- (2024)
Background: Ductal carcinoma in situ (DCIS) can progress to invasive breast cancer (IBC), but often never will. As we cannot predict accurately which DCIS-lesions will or will not progress to IBC, almost all women with DCIS undergo breast-conserving
Externí odkaz:
https://doaj.org/article/bc84270199394f7bb7028854a77ee924
Autor:
Sena Alaeikhanehshir, Madelon M. Voets, Frederieke H. van Duijnhoven, Esther H. lips, Emma J. Groen, Marja C. J. van Oirsouw, Shelley E. Hwang, Joseph Y. Lo, Jelle Wesseling, Ritse M. Mann, Jonas Teuwen, Grand Challenge PRECISION Consortium Steering Group
Publikováno v:
Cancer Imaging, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background Ductal Carcinoma In Situ (DCIS) can progress to invasive breast cancer, but most DCIS lesions never will. Therefore, four clinical trials (COMET, LORIS, LORETTA, AND LORD) test whether active surveillance for women with low-risk D
Externí odkaz:
https://doaj.org/article/fc3bee61c9014d9a860d6d7699fca1a8
Publikováno v:
PLoS ONE, Vol 9, Iss 2, p e88551 (2014)
IntroductionDespite continuous efforts, not a single predictor of breast cancer chemotherapy resistance has made it into the clinic yet. However, it has become clear in recent years that breast cancer is a collection of molecularly distinct diseases.
Externí odkaz:
https://doaj.org/article/d694dcb5c88a486ab2f015e14107d826
Autor:
Donna O. Debets, Erik L. de Graaf, Marte C. Liefaard, Gabe S. Sonke, Esther H. Lips, Anna Ressa, Maarten Altelaar
Publikováno v:
iScience, Vol 27, Iss 6, Pp 109858- (2024)
Summary: In this study, we measured the kinase activity profiles of 32 pre-treatment tumor biopsies of HER2-positive breast cancer patients. The aim of this study was to assess the prognostic potential of kinase activity levels, to identify potential
Externí odkaz:
https://doaj.org/article/bfdbc26b61c74528a8ee376a35d970f6
Autor:
Witali Aswolinskiy, Enrico Munari, Hugo M. Horlings, Lennart Mulder, Giuseppe Bogina, Joyce Sanders, Yat-Hee Liu, Alexandra W. van den Belt-Dusebout, Leslie Tessier, Maschenka Balkenhol, Michelle Stegeman, Jeffrey Hoven, Jelle Wesseling, Jeroen van der Laak, Esther H. Lips, Francesco Ciompi
Publikováno v:
Breast Cancer Research, Vol 25, Iss 1, Pp 1-15 (2023)
Abstract Background Invasive breast cancer patients are increasingly being treated with neoadjuvant chemotherapy; however, only a fraction of the patients respond to it completely. To prevent overtreatment, there is an urgent need for biomarkers to p
Externí odkaz:
https://doaj.org/article/83850dbe69834722be710c67bd14b3d4
Autor:
Sonja Vliek, Florentine S. Hilbers, Erik van Werkhoven, Ingrid Mandjes, Rob Kessels, Sieta Kleiterp, Esther H. Lips, Lennart Mulder, Mutamba T. Kayembe, Claudette E. Loo, Nicola S. Russell, Marie-Jeanne T. F. D. Vrancken Peeters, Marjo J. Holtkamp, Margaret Schot, Joke W. Baars, Aafke H. Honkoop, Annelie J. E. Vulink, Alex L. T. Imholz, Suzan Vrijaldenhoven, Franchette W. P. J. van den Berkmortel, Jetske M. Meerum Terwogt, Jolanda G. Schrama, Philomeen Kuijer, Judith R. Kroep, Annemieke van der Padt-Pruijsten, Jelle Wesseling, Gabe S. Sonke, Kenneth G. A. Gilhuijs, Agnes Jager, Petra Nederlof, Sabine C. Linn
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-9 (2023)
Abstract Exploratory analyses of high-dose alkylating chemotherapy trials have suggested that BRCA1 or BRCA2-pathway altered (BRCA-altered) breast cancer might be particularly sensitive to this type of treatment. In this study, patients with BRCA-alt
Externí odkaz:
https://doaj.org/article/8df2c3c9b54e4fdaa94ca1a2ca82efc6
Autor:
Sarah B. Gosling, Emily L. Arnold, Samantha K. Davies, Hannah Cross, Ihssane Bouybayoune, Doriana Calabrese, Jayakrupakar Nallala, Sarah E. Pinder, Liping Fu, Esther H. Lips, Lorraine King, Jeffrey Marks, Allison Hall, Lars J. Grimm, Thomas Lynch, Donna Pinto, Hilary Stobart, E. Shelley Hwang, Jelle Wesseling, Kalotina Geraki, Nicholas Stone, Iain D. Lyburn, Charlene Greenwood, Keith D. Rogers, Grand Challenge PRECISION Consortium
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Ductal carcinoma in-situ (DCIS) accounts for 20–25% of all new breast cancer diagnoses. DCIS has an uncertain risk of progression to invasive breast cancer and a lack of predictive biomarkers may result in relatively high levels (~ 75%) of
Externí odkaz:
https://doaj.org/article/0c736cfe79ab4053ba3ef0858002ace5
Autor:
Leonie Voorwerk, Joyce Sanders, Milou S. Keusters, Sara Balduzzi, Sten Cornelissen, Maxime Duijst, Esther H. Lips, Gabe S. Sonke, Sabine C. Linn, Hugo M. Horlings, Marleen Kok
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-10 (2023)
Abstract Immune checkpoint blockade (ICB) is currently approved for patients with triple-negative breast cancer (TNBC), whereas responses to ICB are also observed in a small subgroup of Estrogen Receptor (ER)-positive breast cancer. The cut-off for E
Externí odkaz:
https://doaj.org/article/bf1f76273f634aa69a34a1e2029a1773